To avoid side effects and improve tropism for the tumor, the virus is genetically engineered with the insertion of the human telomerase reverse transcriptase promoter (hTERT), which affects the expression of the adenoviral E1A gene, allowing oncolytic virus replication only in tumor cells (telomerase-positive cells) [75,76]. This evidence concerns the gene DHTKD1 and neoplasm.